5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Sweden In-Vitro Diagnostics Market is segmented by Test ( Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Hematology, Other Types), Product, Usability, Application, and End Users.
The Swedish in vitro diagnostics market is expected to witness a CAGR of 5.2% during the forecast period.
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
|By Test Type|
|Disposable IVD Devices|
|Reusable IVD Devices|
|Hospitals & Clinics|
|Other End Users|
Report scope can be customized per your requirements. Click here.
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the term of the contract. Many diagnostic companies have in excess of 75% of sales from consumables, such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
To understand key trends, Download Sample Report
The Swedish in vitro diagnostics market is highly competitive and consists of a number of major players. Companies, like Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories Inc., Danaher Corporation, Johnson & Johnson, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific Inc., among others, hold the substantial market share in the Swedish in vitro diagnostics market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.5 Other Types
5.2.3 Other Products
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4.1 Infectious Disease
5.4.5 Autoimmune Disease
5.4.6 Other Applications
5.5 End Users
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals & Clinics
5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson, and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Danaher Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Siemens Healthcare
6.1.9 Thermo Fisher Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments